Aim: To assess the characteristics and long-term outcome after surgery in patients with multiple endocrine neoplasia type 1 (MEN1)-associated insulinoma. Methods: Retrospective analysis of prospectively collected data of MEN1 patients with organic hyperinsulinism at a tertiary referral center. Results: Thirteen (17%) of 74 patients with MEN1 had organic hyperinsulinism. The median age at diagnosis was 27 (range 9-48) years. In 7 patients insulinoma was the first manifestation of the syndrome. All patients had at least one pancreatic neuroendocrine neoplasm (pNEN) upon imaging, including CT, MRI or endoscopic ultrasonography. Seven patients had solitary lesions upon imaging, 4 patients had one dominant tumor with coexisting multiple small pNENs, and 2 patients had multiple lesions without dominance. Eight patients had limited resections (1 segmental resection, 7 enucleations), 4 subtotal distal pancreatectomies, and 1 patient a partial duodenopancreatectomy. There was no postoperative mortality. Six patients experienced complications, including pancreatic fistula in 5 patients. Pathological examination revealed median three (range 1-14) macro-pNENs sized between 6 and 40 mm, and a total of 14 potentially benign insulinomas were detected in the 13 patients. After median follow-up of 156 months, only 1 patient developed recurrent hyperinsulinism after initial enucleation. Twelve patients developed new pNENs in the pancreatic remnant and 4 patients underwent reoperations (3 for metastatic ZES, 1 for recurrent hyperinsulinism). One of 5 patients with an initial extended pancreatic resection developed insulin-dependent diabetes mellitus. Conclusion: Enucleation and limited resection provide long-term cure for MEN1 insulinoma in patients with solitary or dominant tumors. Subtotal distal pancreatectomy should thus be preserved for patients with multiple pNENs without dominance given the risk of exocrine and endocrine pancreas insufficiency in the mostly young patients.

Keywords:
Multiple endocrine neoplasia type 1, MEN1, Insulinoma, Surgery, Enucleation
1.
Brandi ML, Gagl RF, Angeli A, Bilezekian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RC, Librola A, Lips CJM, Lombardi G, Pacini MMF, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA, Maerx SJ: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
2.
Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, Edwards CR, Heath DA, Jackson CE, Jansen S, Lips K, Monson JP, O'Halloran D, Sampson J, Shalet SM, Wheeler MH, Zink A, Thakker RV: Clinical studies of multiple endocrine neoplasia type 1 (MEN1). Q J Med 1996;89:653-669.
3.
Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA: Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 1998;129:484-494.
4.
Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi ML: Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012;97:2990-3011.
5.
Thompson NW, Lloyd RV, Nishiyama RH, Vinik AI, Strodel WE, Allo MD, Eckhauser FE, Talpos G, Mervak T: MEN1 pancreas: a histological and immunohistochemical study. World J Surg 1984;8:561-574.
6.
Mignon M, Ruszieniewski P, Podevin P, Sabbagh L, Cadiot G, Rigaud D, Bonfils S: Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type 1. World J Surg 1993;17:489-497.
7.
Anlauf M, Bauersfeld J, Raffel A, Koch CA, Henopp T, Alkatout I, Schmitt A, Weber A, Kruse ML, Braunstein S, Kaserer K, Brauckhoff M, Dralle H, Moch H, Heitz PU, Komminoth P, Knoefel WT, Perren A, Klöppel G: Insulinomatosis: a multicentric insulinoma disease that frequently causes early recurrent hyperinsulinemic hypoglycemia. Am J Surg Pathol 2009;33:339-346.
8.
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ: Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997;276:404-407.
9.
Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC: Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997;6:1169-1175.
10.
Bartsch DK, Langer P, Wild A, Schilling T, Celik I, Rothmund M, Nies C: Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery 2000;128:958-966.
11.
Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, Gagel RF, Evans DB, Perrier ND. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006;30:643-653.
12.
Schaaf L, Pickel J, Zinner K, Hering U, Höfler M, Goretzki PE, Spelsberg F, Raue F, von zur Mühlen A, Gerl H, Hensen J, Bartsch DK, Rothmund M, Schneyer U, Dralle H, Engelbach M, Karges W, Stalla GK, Höppner W: Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Exp Clin Endocrinol Diabetes 2007;115:509-517.
13.
Thevenon J, Bourredjem A, Faivre L, Cardot-Bauters C, Calender A, Murat A, Giraud S, Niccoli P, Odou MF, Borson-Chazot F, Barlier A, Lombard-Bohas C, Clauser E, Tabarin A, Parfait B, Chabre O, Castermans E, Beckers A, Ruszniewski P, Le Bras M, Delemer B, Bouchard P, Guilhem I, Rohmer V, Goichot B, Caron P, Baudin E, Chanson P, Groussin L, Du Boullay H, Weryha G, Lecomte P, Penfornis A, Bihan H, Archambeaud F, Kerlan V, Duron F, Kuhn JM, Vergès B, Rodier M, Renard M, Sadoul JL, Binquet C, Goudet P: Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'Etude des Tumeurs Endocrines (GTE) cohort study. Hum Mol Genet 2013;22:1940-1948.
14.
Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT: NANETS treatment guidelines. Well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735-752.
15.
Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R, Barcelona Consensus Conference Participants: ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012;95:98-119.
16.
Tonelli F, Fratini G, Falchetti A, Nesi G, Brandi ML: Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J Intern Med 2005;257:38-49.
17.
O'Riordain DS, O'Brien T, van Heerden JA, Service FJ, Grant CS: Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg 1994;18:488-494.
18.
Giudici F, Nesi G, Brandi ML, Tonelli F: Surgical management of insulinomas in multiple endocrine neoplasia type 1. Pancreas 2012;41:547-553.
19.
Rasbach DA, van Heerden JA, Grant C, Carney JA: Surgical management of hyperinsulinism in the multiple endocrine neoplasia, type 1 syndrome. Arch Surg 1985;120:584-589.
20.
Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH: Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery 1991;110:998-1005.
21.
Thompson NW: Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998;243:495-500.
22.
Cougard P, Goudet P, Peix JL, Henry JF, Sarfati E, Proye C, Calender A, GENEM: Les insulinomesdans les néoplasies endocriniennes multiple de type 1 (NEM1): à propos d'une série de 44 cas du groupe d'étude de néoplasies endocriniennes multiples (GENEM). Ann Chir 2000;125:118-123.
23.
Crippa S, Zerbi A, Boninsegna L, Capitanio V, Partelli S, Balzano G, Pederzoli P, di Carlo V, Falconi M: Surgical management of insulinomas. Arch Surg 2012;147:261-266.
24.
Boukhman MP, Karam JH, Shaver J, Siperstein AE, Duh QY, Clark OH: Insulinoma - experience from 1950 to 1995. West J Med 1998;169:98-104.
25.
Zhao YP, Zhan HX, Zhang TP, Cong L, Dai MH, Liao Q, Cai LX: Surgical management of patients with insulinomas: result of 292 cases in a single institution. J Surg Oncol 2011;103:169-174.
26.
Davi MV, Boninsegna L, Carbonare LD, Toaiari M, Capelli P, Scarpa A, Francia G, Falconi M: Presentation and outcome of pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1 syndrome. Neuroendocrinology 2011;94:58-65.
27.
Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, Fernández-del Castillo C: Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 2008;247:165-172.
28.
Grama D, Skogseid B, Wilander E, Eriksson B, Mårtensson H, Cedermark B, Ahrén B, Kristofferson A, Öberg K, Rastand J, Åkerström G: Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J Surg 1992;16:611-619.
29.
Lairmore TC, Chen VC, DeBenedetti MK, Gillanders WE, Norton JA, Doherty GM: Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2000;231:909-918.
30.
Lo CY, Lam KY, Fan ST: Surgical strategy for insulinomas in multiple endocrine neoplasia type I. Am J Surg 1998;175:305-307.
31.
Simon D, Starke A, Goretzki PE, Röher HD: Reoperative surgery for organic hyperinsulinism: indications and operative strategy. World J Surg 1998;22:666-671.
32.
Fernández-Cruz L, Martinez I, Cesar-Borges G, Astudillo E, Orduña D, Halperin I, Sesmilo G, Puig M: Laparoscopc surgery in patients with sporadic and multiple insulinomas associated with multiple endocrine neoplasia type 1. J Gastrointest Surg 2005;9:381-388.
33.
Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH, Rothmund M: Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2005;242:757-766.
34.
Bartsch DK, Kopp I, Bergenfelz A, Rieder H, Münch K, Jäger K, Deiss Y, Schudy A, Barth P, Arnold R, Rothmund M, Simon B: MEN1 gene mutations in 12 MEN1 families and their associated tumors. Eur J Endocrinol 1998;139:416-420.
35.
Waldmann J, Fendrich V, Habbe N, Bartsch DK, Slater EP, Kann PH, Rothmund M, Langer P: Screening of patients with endocrine neoplasia type 1: a critical analysis of its value. World J Surg 2009;33:1208-1218.
36.
Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Büchler M, et al, International Study Group on Pancreatic Fistula Definition: Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005;138:8-13.
37.
Klöppel G, Perren A, Heitz PU: The gastroenteropancreatic neuroendocrine cell system and it tumors: the WHO classification. Ann NY Acad Sci 2004;1014:13-27.
38.
Goretzki P, Starke A; Lammers B, Schwarz K, Röher HD: Pancreatic hyperinsulinism - changes of the clinical picture and importance of differences in sporadic disease course (experience with 144 patients operated in the period 1986-2009). Zentralbl Chir 2010;135:218-225.
39.
Fendrich V, Bartsch DK, Langer P, Zielke A, Rothmund M: Diagnosis and surgical treatment of insulinoma. Dtsch Med Wochenschr 2004;129:941-946.
40.
Tonelli F, Fratini G, Nesi G, et al: Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 2006;244:61-70.
41.
Lopez CL, Falconi M, Waldmann J, Boninsegna L, Fendrich V, Goretzki PK, Langer P, Kann PH, Partelli S, Bartsch DK: Partial duodenopancreatectomy can provide cure for duodenal Zollinger-Ellison syndrome associated with multiple endocrine neoplasia type 1. Ann Surg 2013;257:308-314.
42.
McLean A: Endoscopic ultrasound in the detection of pancreatic islet cell tumors. Cancer Imaging 2004;4:84-91.
43.
Kann PH, Balakina E, Ivan D, Bartsch DK, Meyer S, Klose KJ, Behr T, Langer P: Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 2006;13:1195-1202.
44.
Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage EN, Ahn JM, Kiesewetter DO, Chen X: PET of insulinoma using 18F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm 2011;8:1775-1782.
45.
Wong M, Isa SH, Zahiah M, Azmi KN: Intraoperative ultrasound with palpation is still superior to intra-arterial calcium stimulation test in localising insulinoma. World J Surg 2007;31:586-592.
46.
Proye C, Pattou F, Carnaille B, Lefebvre J, Decoulx M, d'Herbomez M: Intraoperative insulin measurement during surgical management of insulinomas. World J Surg 1998;22:1218-1224.
47.
Carneiro DM, Levi JU, Irvin GL 3rd: Rapid insulin assay for intraoperative confirmation of complete resection of insulinomas. Surgery 2002;132:937-942.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.